Attempts to enhance the eradication rate of Helicobacter pylori infection

doi:10.3748/wjg.v20.i18.5252

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 18

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7843)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

996

WORD

338

HTML

4356

Tables (1-2)

199

Sum=5889

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

894

Download

1059

Sum=1953

May 14, 2014 (publication date) through Jan 7, 2025

Times Cited of This Article

Times Cited (27)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. May 14, 2014; 20(18): 5252-5262
Published online May 14, 2014. doi: 10.3748/wjg.v20.i18.5252

Table 1 Treatment regimens for Helicobacter pylori eradication

Treatment	Regimens	Duration
Standard triple therapy	PPI (standard dose), amoxicillin (1 g), and clarithromycin (500 mg) twice daily	7-14 d
Standard triple therapy	PPI (standard dose), metronidazole (500 mg), and clarithromycin (500 mg) twice daily	7-14 d
Bismuth containing quadruple therapy	PPI (standard dose) twice daily, bismuth (standard dose), metronidazole (500 mg), and tetracycline (500 mg) four times daily	10-14 d
Sequential therapy	PPI (standard dose) and amoxicillin (1 g) twice daily for 5 d, followed by PPI (standard dose), metronidazole (500 mg), and clarithromycin (500 mg) twice daily for 5 d	10 d
Concomitant therapy (Non-bismuth quadruple therapy)	PPI (standard dose), amoxicillin (1 g), metronidazole (500 mg), and clarithromycin (500 mg) twice daily	10 d
Hybrid therapy	PPI (standard dose), amoxicillin (1 g) twice daily for 7 d, followed by PPI (standard dose), amoxicillin (1 g), metronidazole (500 mg), and clarithromycin (500 mg) twice daily for 7 d	14 d
Levofloxacin-based triple therapy	PPI (standard dose), amoxicillin (1 g), and levofloxacin (500 mg) twice daily	10 d
LOAD regimen	Levofloxacin (250 mg) with breakfast, omeprazole (40 mg) before breakfast, nitazoxanide (500 mg) twice daily with meals, and doxycycline (100 mg) at dinner	7 d or 10 d
Rifabutin-based triple therapy	PPI (standard dose), amoxicillin (1 g), and rifabutin (150 mg) twice daily	7-14 d
Furazolidone-based quadruple therapy	Lansoprazole (30 mg), tripotassiumdicitratobismuthate (240 mg), tetracycline (1 g), and furazolidone (200 mg) twice daily	7 d
Novel quadruple therapy	PARC; rabeprazole (20 mg, thrice daily for 10 d), amoxicillin (1000 mg, thrice daily for 10 d), rifabutin (150 mg, starting from day 6, twice daily for 5 d), and ciprofloxacin (500 mg, starting from day 6, twice daily for 5 d)	10 d
Novel quadruple therapy	PBRC (allergic to amoxicillin); rabeprazole (20 mg, thrice daily for 10 d), bismuth subcitrate (240 mg, 4 times daily for 10 d), rifabutin (150 mg, twice daily for 10 d), and ciprofloxacin (500 mg, twice daily for 10 d)	10 d
High dose dual therapy	Lansoprazole (30 mg) and amoxicillin (750 mg) thrice daily	14 d

PPI: Proton pump inhibitor.

Citation: Bang CS, Baik GH. Attempts to enhance the eradication rate of Helicobacter pylori infection. World J Gastroenterol 2014; 20(18): 5252-5262
URL: https://www.wjgnet.com/1007-9327/full/v20/i18/5252.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i18.5252